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INTRODUCTION 
 
Superior vena cava (SVC) syndrome is a common 
complication of malignancy, particularly in lung cancer. It 
is evident in 4% of lung cancer patients at diagnosis (1), 
and it may also develop during the disease course. Patients 
with malignant SVCS are typically seriously ill, and further 
deterioration is likely, due to the presence of unresectable 
advanced malignant tumors. Although bypass surgery has 
been reported for palliative treatment of malignant SVCS 
in selected patients (2), this type of surgery in terminally 
ill patients is difficult to justify and rather invasive for 
a palliative procedure. Until recently, radiotherapy and 
chemotherapy were standards in the management of 
malignant SVCS (3, 4). However, both therapies may not 
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be possible under certain conditions, especially when the 
cumulative maximum dosage has been reached in previous 
treatments. In addition, it may take several weeks before 
either intervention shows a clinical effect (5).
Endovascular stent placement as an alternative palliative 
treatment has increased because it is fastest way to relieve 
symptoms (6). Many studies have reported the efficacy 
of stent placement in patients with malignant SVCS (7-
10). A few reports have described stent-graft placement 
in recurrent SVCS after bare metallic stent placement or 
iatrogenic injury of the SVC (11-14). However, initial 
placement of stent-grafts for the treatment of malignant 
SVCS has not been reported. Thus, we report on successful 
outcomes after the placement of stent-grafts for two 
patients who had malignant SVCS caused by squamous cell 
carcinoma. 
CASE REPORTS 
Case 1
A 74-year-old man presented with chest pain, anorexia, 
and dyspnea. A chest radiograph showed an ill-defined 
mass in the right upper lung field. Computed tomography 
(CT) revealed an ill-defined infiltrating central mass with 
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mediastinal lymphadenopathy. The patient underwent a 
bronchoscopy and biopsy. Histology confirmed the diagnosis 
of squamous cell carcinoma and consequently, the patient 
underwent four cycles of chemotherapy for two months. 
The patient then presented with swelling of the face and 
severe dyspnea for a week. Subsequent CT demonstrated 
progression of the mass, obstruction of the SVC, confluence 
of both brachiocephalic veins (Fig. 1A), and right 
brachiocephalic venous thrombosis (Fig. 1B). 
Although thrombolysis of the right brachiocephalic 
thrombosis and subsequent bilateral stenting could be 
performed, there was a risk of complications following 
thrombolysis because of the patient’s advanced age. We 
thus decided on the unilateral placement of a triple-
layered stent-graft (Vascular ComVi stent-graft, TaeWoong 
Medical, Gimpo, Korea) that was 5 mm long at both bare 
extensions (Fig. 1C). The triple-layered stent-graft was 
composed of two uncovered nitinol self-expanding metallic 
stents and an expanded polytetrafluoroethylene (ePTFE) 
membrane between two uncovered stent layers. The wire 
was exposed on both the inner and outer surfaces. The 
stent-graft was mounted onto an 8.5-Fr stent introducer 
set. After puncture of the right common femoral vein, a 
9-Fr sheath was inserted. Left brachiocephalic venography 
demonstrated obstruction of the SVC and confluence (Fig. 
1D). The pressure gradient between the left brachiocephalic 
vein and distal SVC was 24 mm Hg. Predilatation using 
a 10-mm-diameter balloon catheter (Boston Scientific, 
Galway, Ireland) was performed to determine the stent 
size and allow for the easy navigation of the stenosis as 
well as placement of the stent. Venography revealed that 
the length of the lesion was approximately 3 cm and the 
diameter of the SVC was approximately 12 mm. To prevent 
proximal and distal tumor overgrowth, a 14 mm x 8 cm 
stent-graft was introduced over a 0.035-inch, 180-cm-
long extra stiff Amplatz guide-wire (Cook, Bloomington, 
IN, USA), which was deployed successfully across the 
stenosis (Fig. 1E). Post-stenting balloon dilation of the 
stent was then performed using a 10 mm x 4 cm balloon 
catheter. Venography immediately after stent placement 
confirmed the correct positioning of the stent and the 
pressure gradient decreased to 6 mm Hg. Clinical symptoms 
improved immediately after stent placement. The patient 
did not receive any prophylactic anticoagulation after stent 
placement. CT performed after 11 months demonstrated 
good stent patency without migration (Fig. 1F). The patient 
died at home 14 months after stent placement. At the time 
of death, the patient showed no recurrent symptoms of 
SVCS, suggesting continued patency of the stent. 
 
Case 2
A 77-year-old man presented with cough, whitish 
sputum, and dyspnea. A chest radiograph showed an ill-
defined mass in the right upper lung field. CT revealed 
an ill-defined infiltrating central mass and a mediastinal 
lymphadenopathy. The patient underwent bronchoscopy 
and biopsy. Histology confirmed the diagnosis of squamous 
cell carcinoma and the patient underwent four cycles of 
chemotherapy for three months. The patient then presented 
with swelling of the face and severe dyspnea for 10 days. 
Subsequent CT demonstrated progression of the mass and 
obstruction of the SVC caused by the mass and mediastinal 
lymphadenopathy (Fig. 2A). 
Right internal jugular venography via the right common 
femoral vein demonstrated obstruction of the SVC with 
venous collateral development (Fig. 2B). The pressure 
gradient between the right internal jugular vein and distal 
SVC was 21 mm Hg. Venography revealed that the length 
of the lesion was approximately 4.5 cm and the diameter 
of the SVC was approximately 11 mm. A 14 mm x 8 cm 
stent-graft (Fig. 2C) was successfully inserted. To prevent 
brachiocephalic vein occlusion by the stent-graft, the 
distal end of the stent-graft was deployed just beneath the 
confluence. Venography immediately after stent placement 
confirmed the correct positioning of the stent and the 
pressure gradient decreased to 7 mm Hg. Clinical symptoms 
improved immediately after stent placement and did not 
receive any prophylactic anticoagulation. CT performed 
after four months demonstrated good stent patency without 
migration (Fig. 2D). The patient died at home seven 
months after stent placement. At the time of death, the 
patient showed no recurrent symptoms of SVCS, suggesting 
continued patency of the stent.
DISCUSSION
Endovascular stenting may be used as a first-line 
therapeutic measure in patients with malignant SVCS 
because stenting does not interfere with subsequent 
antitumor treatments and provides urgent relief of 
symptoms (6, 8). Additionally, endovascular stenting 
greatly improves the quality of life of patients, who usually 
have a short life expectancy (8). Although many studies 
have reported the efficacy of endovascular stenting in Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 229
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patients with malignant SVCS, recurrence following initial 
successful stenting still occurs in up to 18% of cases (10), 
and is attributed to tumor ingrowth inside the stent or 
venous thrombosis. However, most patients with malignant 
SVCS have a short life expectancy and the stent remains 
patent until death. Furthermore, stent occlusion can be 
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Fig. 1. Seventyfour-year-old man with malignant superior vena cava syndrome due to squamous cell carcinoma. 
A. Contrast-enhanced axial CT image shows central mass with mediastinal lymphadenopathy and left brachiocephalic venous obstruction (arrow). B. 
Axial CT image at upper level of A shows right brachiocephalic venous thrombosis (arrow). C. Partially expanded polytetrafluoroethylene-covered 
stent-graft used in these cases. D. Left brachiocephalic venography shows obstruction of confluence and proximal superior vena cava (arrow). E. 
Venography after stent-graft placement (14 mm x 8 cm) (arrowheads) shows fluent passage of contrast medium via stent. F. Contrast enhanced 
axial CT image obtained 11 months after stent-graft placement shows patent stent-graft.Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 230
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treated with thrombolysis, balloon dilation, or further stent 
insertion with good secondary patency rates. However, 
secondary endovascular treatments are sometimes difficult 
and have additional costs. Anticoagulation therapy is often 
prescribed for patients with malignant SVCS after stenting, 
although its efficacy has not been clearly confirmed (8). 
Moreover, determining the status of optimum anticoagulant 
therapy is difficult (10). Thus, to prevent stent occlusion 
and improve the patency rate of stents, we thought that it 
was important to prevent tumor ingrowth into the stents. 
This had led to the study of stent-grafts that are effective 
in preventing tumor ingrowth and subsequent stent 
occlusion. 
Endovascular stent-graft placement has been used 
for emergency repair of the SVC (13, 14). Another case 
involved repair of recurrent SVC obstruction that occurred 
immediately or three weeks after metallic stent placement 
(11, 12). To our knowledge, in contrast to previously 
reported cases, our cases are the first to include the primary 
placement of an ePTFE-covered stent in patients with 
malignant SVCS. 
Prior to using a stent-graft, a few technical points 
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Fig. 2. Seventyseven-year-old man with malignant superior vena cava syndrome due to squamous cell carcinoma. 
A. Contrast-enhanced coronal CT image shows superior vena cava obstruction caused by central lung mass (asterisk). B. Right brachiocephalic 
venography shows obstruction of proximal superior vena cava (arrow) with collaterals. C. Venography after stent-graft placement (14 mm x 8 cm) 
(arrowheads) shows fluent passage of contrast medium via stent. D. Contrast-enhanced coronal CT image obtained four months after stent-graft 
placement shows patent stent-graft.Korean J Radiol 13(2), Mar/Apr 2012 kjronline.org 231
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deserve special mention. First, risk of stent migration 
exists: stent migration remains a significant long term 
complication and is occasionally fatal (15). Stent migration 
occurred in neither of our cases because the partially 
covered stent with both bare extensions and outer bare 
stent design might have prevented stent migration. 
Additionally, selection of a slightly oversized stent might 
also prevent migration. Generally, to avoid stent migration, 
the diameter of the stent should be 10-20% greater than 
that of the lesion (7). Second, placing a long length graft 
at the confluence of the brachiocephalic veins carries the 
risk of occlusion of the contralateral branch. This could 
potentially lead to thrombosis of the upper extremity veins. 
However, when both brachiocephalic veins were invaded by 
the tumor, unilateral brachiocephalic vein revascularization 
was sufficient and provided higher flow through the graft 
than when both brachiocephalic veins were revascularized 
(16). Nagata et al. (7) suggested that unilateral relief of 
obstruction may allow collateral flow from the contralateral 
vein via the cervical and intracranial route. The Case 1 
patient, in whom the stent-graft was placed from the SVC 
to the left brachiocephalic vein, experienced symptomatic 
relief. Follow-up CT images confirmed patency of the stent-
graft and contralateral veins via collateral flow of the 
cervical route. 
In conclusion, the two study cases demonstrate the 
potential efficacy of stent-graft placement for the palliative 
treatment of malignant SVCS. Stent-graft placement appears 
to be a safe and effective method. Both patients were 
asymptomatic until their deaths 7 and 14 months after, 
respectively. However, further investigation is necessary 
because the patency of the stent-graft in the venous system 
remains to be determined. 
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